Psyence Group Inc.

OTC: PSYGF · Healthcare · Drug Manufacturers - General

Canadian filerHQ Toronto, ONReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 23

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, return on assets · ↓ listing tenure, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$287.7k

Employees

—

Market cap

$2.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$287.7k-400.2k CAD2025

Operating income-$4.0M-5.5M CAD2025

Total assets$7.4M10.6M CAD2025

Liabilities$739.9k1.1M CAD2025

Equity$895.4k1.3M CAD2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Psyence Group Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Relevium Technologies Inc.——Ernexa Therapeutics Inc.42D ProtoKinetix, Incorporated——Sonoma Pharmaceuticals, Inc.59C

Key facts

CEOJody Aufrichtig

SectorHealthcare

IndustryDrug Manufacturers - General

HeadquartersToronto, ON

ExchangeOTC: PSYGF

Employees—

IPO date2022-05-31

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.